Business Wire

MCR Acquires Cloud-Based Hotel Management Platform Optii

7.12.2021 17:00:00 EET | Business Wire | Press release

Share

MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations.

Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein.

MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements.

Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii.

A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning sequences for faster turnaround times and reduced costs. With its Service and Chat products, Optii streamlines internal communication, allowing managers to auto-assign and track jobs and guest requests in real time, eliminating calls by 95%. The user-friendly mobile and tablet interface can be accessed anywhere, whether on or off property.

Used by hotels to clean more than 10 million guestrooms globally, Optii has experienced stratospheric growth in the past year as hoteliers seek to increase housekeeping productivity while committing to Covid-19 protocols and facing labor shortages.

Fully configurable, the platform connects to many property management systems and is a best-in-class solution for hotels of all sizes, from 50-room boutique properties to 3,000-room casinos. Unlike any other hotel technology, remote onboarding is led by the experts — former executive housekeepers. The software’s artificial intelligence gets smarter over time — around week four, the technology peaks in providing operational efficiencies.

Optii has an aggressive expansion strategy that includes the imminent introduction of a Preventative Maintenance product.

Katherine Grass, CEO of Optii, says, “We are honored to have been selected by MCR to join their portfolio of companies. This acquisition will significantly boost our ability to provide hotels around the world with the technology they need to succeed in today’s operating environment. More and more hotels are realizing that investing in the right technology at this unique time can be a key lever for success. This is a huge growth opportunity for our company to continue momentum in the United States and Europe as well as to further develop our leadership position in Asia.”

Adds Tyler Morse, Chairman and CEO of MCR, “Innovation is a core value of MCR and the acquisition of Optii forwards our mission. At our 140 hotels, we have used every housekeeping technology on the market — and Optii is simply the best. MCR’s investment in Optii will expand its reach globally and provide the company with the resources to continue introducing cutting-edge technology to the hotel industry.”

About Optii Solutions

Optii, headquartered in Austin, Texas, and with offices in New York, London and Brisbane, is a hotel operations solution that leverages smarter technologies such as artificial intelligence, analytics, messaging and mobility to improve the efficiency and effectiveness of hotel operations teams. Optii operates in real time and allows hotels to streamline operations, reduce costs and enhance the guest experience in proven and tangible ways, without requiring capital expenditure and complex integrations. Optii is used by hotels around the world, including the Venetian Macau, part of Las Vegas Sands, La Cantera Resort & Spa and The Don Cesar in the United States, Okada Manilla Resort & Casino, Doma Hotels, Marriott, IHG and more. For further information about Optii, please visit optiisolutions.com.

About MCR

  • 4th-largest hotel owner-operator in the United States
  • $4.0 billion portfolio of 140 premium-branded hotels
  • MCR operates 8 Marriott brands, 6 Hilton brands and a number of unflagged independent hotels
  • 20,000 guestrooms across 34 states and 84 cities
  • Founded in 2006
  • Offices in New York City, Dallas, Chicago and Richmond, Virginia
  • 4,000 team members across the country
  • Three-time recipient of the Marriott Partnership Circle Award , the highest honor Marriott presents to its owner and franchise partners
  • Recipient of the Hilton Legacy Award for Top Performer
  • For the TWA Hotel at New York’s JFK Airport, MCR won the Development of the Year (Full Service) Award at The Americas Lodging Investment Summit (ALIS) , the Urban Land Institute New York Excellence in Hotel Development Award and the American Institute of Architects national Architecture Award, the highest honor given by the AIA
  • Named one of Fast Company’s 10 Most Innovative Travel Companies of 2020
  • For more information, please visit mcrhotels.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ellie Box: ebox@fireoth.com, +44 7974 791119
Sarah Mulder: smulder@fireoth.com, +44 7720401466

info@mcrhotels.com
(203) 682-8277

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye